MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company trading near its 52-week low of $2.99, has announced the initiation of a Phase 3 trial for its Alzheimer's disease ...

The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...

Trusted resource of information on Alzheimer's Disease that includes articles, news, videos, animations, quizzes, calculators ...

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...

Scientists from DZNE, University Hospital Bonn (UKB) and the University of Bonn provide new evidence that preventing brain inflammation is a promising approach for the treatment of Alzheimer's disease ...

An international research team has identified key genetic factors that confer protective effects against Alzheimer's disease (AD) through a comprehensive genetic analysis of East Asian populations, ...

MALVERN, PA - Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, has successfully closed its public offering, generating $21 million in gross ...

A new study showed that people who took longer to enter this dream phase of sleep had higher levels of amyloid beta and tau, ...

Scientists from DZNE , University Hospital Bonn (UKB) and the University of Bonn provide new evidence that preventing brain inflammation is a ...

The researchers theorise the protective effects of these drugs could be because they reduce inflammation, control infections ...